Immunomodulatory effect of long-term oclacitinib maleate therapy in dogs with atopic dermatitis.

Autor: De Caro Martins G; CentroVet, Veterinary Specialties, 42 Raul Mendes St, Belo Horizonte, MG, 30010-030, Brazil., da Costa-Val AP; Clinics and Surgery Department, Veterinary School, Presidente Antonio Carlos Av, 6627, Belo Horizonte, MG, 31270-901, Brazil., Coura FM; Veterinary Department, Bambuí/Medeiros Road, Km 05 Faz, Varginha, MG, 38900-000, Brazil., Diamantino GML; Clinics and Surgery Department, Veterinary School, Presidente Antonio Carlos Av, 6627, Belo Horizonte, MG, 31270-901, Brazil., Nogueira MM; Clinics and Surgery Department, Veterinary School, Presidente Antonio Carlos Av, 6627, Belo Horizonte, MG, 31270-901, Brazil., de Oliveira Melo-Junior OA; Celular Interactions Biology, Morfology Department, Biological Sciences Institute, Presidente Antonio Carlos Av, 6627, Belo Horizonte, MG, 31270-901, Brazil., Giunchetti RC; Celular Interactions Biology, Morfology Department, Biological Sciences Institute, Presidente Antonio Carlos Av, 6627, Belo Horizonte, MG, 31270-901, Brazil., da Silveira-Lemos D; Universidade José Do Rosário Vellano 50 Indaiá St, UNIFENAS, Belo Horizonte, MG, 31270-020, Brazil., Melo MM; Clinics and Surgery Department, Veterinary School, Presidente Antonio Carlos Av, 6627, Belo Horizonte, MG, 31270-901, Brazil.
Jazyk: angličtina
Zdroj: Veterinary dermatology [Vet Dermatol] 2022 Apr; Vol. 33 (2), pp. 142-e40. Date of Electronic Publication: 2021 Nov 07.
DOI: 10.1111/vde.13037
Abstrakt: Background: Canine atopic dermatitis (cAD) is a chronic disease characterised by hypersensitivity to environmental allergens. Oclacitinib maleate selectively inhibits pro-inflammatory mediators associated with cAD. However, the impact of chronic oclacitinib use on immunocompetence requires further investigation.
Objectives: Herein, we examined the potential immunomodulatory effects of prolonged oclacitinib treatment in dogs.
Animals: Thirteen privately owned dogs with cAD, treated with 0.4-0.6 mg/kg oclacitinib for 12 months.
Methods and Materials: Pruritus level was evaluated using a pruritus Visual Analog Scale (pVAS) and the canine atopic dermatitis extent and severity index, 4 th iteration (CADESI IV). Peripheral blood samples were collected for routine laboratory assays and lymphocyte subtypes were analysed using flow cytometry. Antigen-specific intracellular cytokine production from CD4+ and CD8+ T lymphocytes was analysed following in vitro stimulation by Dermatophagoides farinae antigens.
Results: Oclacitinib treatment significantly reduced pVAS and CADESI-04 scores, by 51% and 86.7%, respectively. Flow cytometric analysis revealed increased CD4+ and CD14+ lymphocyte populations. The cytokine profile at 360 days after treatment initiation was similar to that before treatment and was not associated with clinical relapse.
Conclusion: Oclacitinib, when administered at the currently labelled dose for one year, is associated with a significant increase in circulating CD4+ T cells, but does not alter cytokine production from antigen-stimulated T cells. The results reported do not support evidence for immunosuppression mediated by the mechanisms evaluated in this study.
(© 2021 ESVD and ACVD.)
Databáze: MEDLINE
Externí odkaz: